



Department
of
Health Economics
HUNHTA

Corvinus Health Policy and Health Economics Conference Series 2018/1

Department of Health Economics, Corvinus University of Budapest

in cooperation with:

Health and Health Care Economics Section of the Hungarian
Economic Association

Health Economics Study Circle, Corvinus University of Budapest

Pharmacoeconomics - Perspectives from the Pharmaceutical Industry

Dr. Tamás Koncz, MD. PhD. Chief Medical Officer (CMO) for
the Inflammation and Immunology (I&I) Unit at Pfizer,
New York, US

INVITATION





Department
of
Health Economics
HUNHTA

Corvinus Health Policy and Health Economics Conference Series 2018/1

Corvinus University of Budapest, Faculty of Economics, Department of Health Economics,

in cooperation with:

Health and Health Care Economics Section of the Hungarian Economic Association
Health Economics Study Circle, Corvinus University of Budapest

Pharmacoeconomics - Perspectives from the Pharmaceutical Industry

Corvinus University of Budapest

February 13, 2018

Room S. Asor. S1

15:30-17:20

H-1093 Budapest, Fővám tér 13-15.¹

¹ <https://goo.gl/maps/CD1yKNj82QL2>

Conference chairperson:

Prof. Márta Péntek, Department of Health Economics, Faculty of Economics, Corvinus University of Budapest

Program

15:30 – 15:40 Welcome - Prof. László Gulácsi, Vice-rector for Research & Department of Health Economics, Corvinus University of Budapest

15:40 – 16:40 Dr. Tamás Koncz, MD, PhD, Chief Medical Officer (CMO) for the Inflammation and Immunology (I&I) Unit at Pfizer, New York, US

Pharmacoeconomics - Perspectives from the Pharmaceutical Industry

16:40 – 17:20 Discussion

17.20 – 18.40 Zsuzsanna Beretzky, PhD student, Department of Health Economics, Corvinus University of Budapest

Cost-of-illness studies in the Central and Eastern European Countries

Omar Rashdan, PhD student, Department of Health Economics, Corvinus University of Budapest

Health economics analysis in the countries of the Middle-East

Discussion

18:40 – 18:50 Take home message & Closing

Valentin Brodszky, MD, MSc, PhD, habil., associate professor, Department of Health Economics, Corvinus University of Budapest

Dr. Tamás Koncz MD, PhD



Dr Tamás Koncz is Chief Medical Officer (CMO) for the Inflammation and Immunology (I&I) Unit at Pfizer, a world-leading biopharmaceutical company. As CMO, Tamás leads the medical affairs department within I&I. Medical affairs professionals across the world at Pfizer belong to a highly trained group of medical doctors and other health care professionals who are responsible for advancing the safe and effective use of Pfizer I&I medicines (including Enbrel, Xeljanz and Eucrisa) as well as continuous data generation and dissemination to advance the understanding of the medicines' benefit:risk profiles. Medical affairs are also involved in research and development, regulatory affairs, reimbursement and payer discussions and lifecycle management of the medicines.

Throughout his career Tamás has worked as medical adviser, health economist and then global medical director for several medicines.

Tamás holds a Medical Degree from the University of Debrecen, MSc in Economics from Corvinus University, MSc in Health Economics (University of York), MSc in Pharmaceutical Medicine (University of Surrey) and a PhD from Semmelweis University (supervisor Prof. László Gulácsi).

Selected publications

Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. *RMD Open*. 2016 Sep 28;2(2):e000308. eCollection 2016.

Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T, Krishnaswami S, Wallenstein G, Wilkinson B, Zwillich SH, Keystone E. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. *Int J Rheum Dis*. 2016 Dec;19(12):1216-1225. doi: 10.1111/1756-185X.12901. Epub 2016 Jul 25. Review.

Strand V, van Vollenhoven RF, Lee EB, Fleischmann R, Zwillich SH, Gruben D, Koncz T, Wilkinson B, Wallenstein G. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. *Rheumatology (Oxford)*. 2016 Jun;55(6):1031-41. doi: 10.1093/rheumatology/kev442. Epub 2016 Feb 29.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*. 2014 Jun 19;370(25):2377-86.

Rendas-Baum R, Bayliss M, Kosinski M, Raju A, Zwillich SH, Wallenstein GV, Koncz T. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective. *Curr Med Res Opin*. 2014 Jul;30(7):1391-403. doi: 10.1185/03007995.2014.896328. Epub 2014 Apr 9. Review.

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a

randomized trial. *Ann Intern Med.* 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet.* 2013 Feb 9;381(9865):451-60. doi: 10.1016/S0140-6736(12)61424-X. Epub 2013 Jan 5.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Mejjide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med.* 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. Erratum in: *N Engl J Med.* 2013 Jul 18;369(3):293.

Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor- α inhibitors. *Arthritis Res Ther.* 2011 Feb 16;13(1): R25. doi: 10.1186/ar3249. PubMed PMID: 21324169; PubMed Central PMCID: PMC3241369.

Koncz T, Pentek M, Brodsky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. *Expert Opin Biol Ther.* 2010 Sep;10(9):1367-78. doi: 10.1517/14712598.2010.510508. Review.

Emery P, Koncz T, Pan S, Lowry S. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. *Clin Ther.* 2008 Jan;30(1):70-83. doi: 10.1016/j.clinthera.2008.01.016.

Hughes D, Cowell W, Koncz T, Cramer J; International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. *Value Health.* 2007 Nov-Dec;10(6):498-509. Review.

Muszbec N, Koncz T, V Hajdú P, Adány R. [Economic evaluation of population-based mass screening for the early detection of cancer: a systematic review]. *Magy Onkol.* 2002;46(2):119-29. Epub 2002 Aug 29. Review. Hungarian.

Zsuzsanna Beretzky

Zsuzsanna Beretzky graduated as an economist at Corvinus University of Budapest in 2016. She started her PhD studies in 2016 at the Health Economics Faculty of the Doctoral School of Management and Business Administration at the Corvinus University. (Supervisors: László Gulácsi, Márta Péntek). Her areas of interest are health-related quality of life in chronic diseases with special focus on EQ-5D studies.



Omar Rashdan

Omar Rashdan graduated as a pharmacist from Jordan University of Science and Technology in 2009 and later as a pharmaceutical technologist with an MSc degree from the University of Bradford. He worked Hikma Pharmaceuticals from 2014 to 2017. He started his PhD studies in 2017 at the Healthcare Management Faculty of the Doctoral School of Management and Business Administration at the Corvinus University. (Supervisors: Valentin Brodszky, László Gulácsi).

